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Background: A caesarean section (CS) can cause a defect or disruption of the myometrium at the site of the
uterine scar, called a niche. In recent years, an association between a niche and postmenstrual spotting after a CS
has been demonstrated. Hysteroscopic resection of these niches is thought to reduce spotting and menstrual pain.
However, there are no randomised trials assessing the effectiveness of a hysteroscopic niche resection.
Methods/Design: We planned a multicentre randomised trial comparing hysteroscopic niche resection to no
intervention. We study women with postmenstrual spotting after a CS and a niche with a residual myometrium of
at least 3 mm during sonohysterography. After informed consent is obtained, eligible women will be randomly
allocated to hysteroscopic resection of the niche or expectant management for 6 months.
The primary outcome is the number of days with postmenstrual spotting during one menstrual cycle 6 months
after randomisation. Secondary outcomes are menstrual characteristics, menstruation related pain and experienced
discomfort due to spotting or menstrual pain, quality of life, patient satisfaction, sexual function, urological
symptoms, medical consultations, medication use, complications, lost productivity and medical costs. Measurements
will be performed at baseline and at 3 and 6 months after randomisation. A cost-effectiveness analysis will be
performed from a societal perspective at 6 months after randomisation.
Discussion: This trial will provide insight in the (cost)effectiveness of hysteroscopic resection of a niche versus
expectant management in women who have postmenstrual spotting and a niche with sufficient residual
myometrium to perform a hysteroscopic niche resection.
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Caesarean section (CS) rates are rising globally. In the
UK the CS rate increased from 12 to 29 % between 1990
and 2008 [1]. In the United States, one in three women
delivered by CS in 2011 [1, 2], whereas in China the
rates have even risen from 2 % in 1985 to 36–58 % in
2010 [3] The strongest increase was seen in Brazil from
15 % in 1970 to even 80 % in the private sector in 2004
[4]. This increasing CS rate has stimulated an interest in
the potential long-term morbidity of CS scars.
BijdeVaate et al. and van der Voet et al. reported a dis-
ruption of the myometrium in the uterine scar of a CS
seen with saline or gel infusion sonography in approxi-
mately 60 % of women who had undergone a CS [5, 6].
Such a disruption or “defect” is called a niche (Fig. 1)
[7]. Studies reported sonohysterography to be the most
accurate method to identify and measure a niche [5, 6, 8].
Small niches, that are also reported to be associated with
bleeding symptoms, can be missed using transvaginal
sonography without contrast [5, 6].
Prolonged menstrual bleeding and postmenstrual spot-
ting are associated with a niche [5, 6, 9–13]. Two inde-
pendent cohort studies reported that approximately
30 % of women with a niche experience postmenstrual
spotting of more than 2 days versus approximately 15 %
of women without a niche after CS [5, 6].
The etiology of niche related postmenstrual spotting
and pain has not been fully elucidated. They are thought
to be caused by retention of menstrual blood in a niche,
which is intermittently expelled after the majority of the
menstruation has ceased [11, 14–16]. Blood can also
accumulate, if fibrotic tissue in the myometrium at the
site of the caesarean scar may impair normal contrac-
tions and as a consequence the drainage of menstrual
flow [11]. Additionally, newly formed fragile vessels inFig. 1 Sonohysterographic visualisation of a niche. The arrow indicates
a disruption of the myometrium in the anterior wall of the uterus over
a distance of approximately 15 mmthe niche may also attribute to the accumulation of
blood or fluid in the niche or uterine cavity due to a
constant low production of in situ leakage of blood
and fluid. This is supported by the presence of free
blood cells in the endometrial stroma, suggesting re-
cent haemorrhage [17] and hysteroscopic evaluations
where small vessels in the majority of patients are
seen (Fig. 2) [15, 18–23].
A few studies reported that niche related menstrual
bleeding disorders or cyclic pain do often not respond
to hormonal therapies, however some comments can
be made concerning the methodology of these studies
[22, 24]. Some authors have recommended hysterectomy
as a treatment for niche related bleeding complaints, but
the exact number of patients undergoing a hysterectomy
due to niche related bleeding disorders is yet unknown
[11, 14, 25]. It is expected that niche related symptoms are
associated to considerable direct and indirect costs, taking
into account medical consultation, therapy (including
hysterectomy) and absence from work.
Since many reports identified an association be-
tween niches and menstrual bleeding disorders after
CS [5, 6, 9, 12, 13] several surgical therapies i.e. laparo-
scopic or hysteroscopic nicheresection or (laparoscopic
assisted) vaginal niche repair, have been developed [26].
Of these treatments, hysteroscopic resection of the niche
is the least invasive one. Resecting the distal rim aims at
improving outflow of menstrual blood. Concurrently
superficial coagulation of vessels in the niche aims at re-
ducing blood loss from these fragile vessels.
So far only a few studies reported on a hysteroscopic
resection of the niche with coagulation of the niche sur-
face [16, 17, 20–24]. These procedures were reported toFig. 2 Niche surface during hysteroscopic evaluation of proximal part
of the niche, several small vessels that easily bleed can be visualised
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complaints in 97 % of the cases and no complications
occurred [26]. The reduction in spotting days after the
procedure compared to baseline was reported in three
studies, mean reduction in spotting varied from 2 to
4 days [18, 21, 27].
Thus reported outcomes are promising. However, the
methodological quality of these studies is low. Follow-up
or validated tools to measure outcomes such as blood
loss or quality of life are mostly not reported, most
studies are case series or retrospective cohorts and
adequately powered prospective comparative studies are
lacking [26]. In addition, none of the studies evaluated
the effect of hysteroscopic niche resection on quality of
life, sexual function, recovery or cost. Before hystero-
scopic niche resection is implemented in women that
suffer from postmenstrual spotting based on a niche,
better assessment of the effectiveness of the treatment is
needed.
In view of these arguments, we designed a randomised
controlled trial to evaluate the (cost) effectiveness of a
hysteroscopic niche resection.Methods/Design
Design
The study is a multicentre randomised controlled super-
iority trial and will be performed in hospitals that col-
laborate within the Dutch Consortium for Studies in
Women’s Health and Reproduction. Participating centres
can be district, teaching or university hospitals. The hospi-
tals are selected based on the presence of extensive experi-
ence of their gynaecologists in advanced hysteroscopic
procedures, such as hysteroscopic resections of large sub-
mucosal fibroids. Gynaecologists will be additionally
trained in their centre in the measurement of a niche and
in performing a hysteroscopic niche resection by one of
the experienced gynaecologists that performed niche
resections in a previous pilot study (J. Huirne, L. van der
Voet or H. Brölmann).
One of the experienced gynaecologists will be present
during the first hysteroscopic niche resection and if
needed also during following hysteroscopic niche resec-
tions in each centre.Participants/eligibility criteria
We will study women who developed postmenstrual
spotting after a CS, and in whom sonohysterography has
shown a niche of at least 2 mm depth and a residual
myometrium of at least 3 mm. Postmenstrual spotting is
defined as two or more days of intermenstrual spotting
or as two or more days of brownish discharge immedi-
ately after the menstrual period in case the total period
of the menstrual bleeding exceeds 7 days, if the period isshorter then 7 days the brownish discharge is considered
to be normal.
In these women, saline or gel sonohysterography (SIS
or GIS) will be performed as part of routine diagnostic
work-up for identification of the origin of the bleeding.
Exclusion criteria are a residual myometrium less than
3 mm at sonohysterography, age below 18 years, preg-
nancy, a (suspected) malignancy, contra-indications for
spinal of general anaesthesia, uterine or cervical polyps,
submucosal fibroids, atypical endometrial cells, cervical
dysplasia, cervical or pelvic infection, hydrosalpinx that
communicates with the uterus or an irregular cycle
(>35 days or intercycle variation of 2 weeks or more).
Procedures, recruitment, randomisation, collection of
baseline data
Before study entry, the niche will be measured with
transvaginal sonography and saline or gel infusion son-
ography in the sagittal plane where the largest niche is
visible and in the transversal plane where the niche is
largest i.e. with the thinnest residual myometrium.
Depth, residual myometrium and the shape of the niche
will be registered (see Fig. 3a, b and c). For inclusion, a
niche needs to be at least 2 mm deep and the residual
myometrium should not be less than 3 mm in one of the
planes during SIS or GIS, given the anticipated risk on
perforation or bladder injuries with a smaller residual
myometrium. Position of the uterus, fluid in the uterine
cavity and/or niche, abnormalities of the fallopian tubes
and/or ovaries are also registered. A cervical PAP-smear
will be obtained to ensure the absence of cervical
dysplasia.
Eligible women will be informed about the study by
one of the gynaecologists, residents or research nurse in
the participating centre. The informed consent form
must be signed before involvement in any study related
activity. After written informed consent is obtained, eli-
gible women will be randomly allocated to hysteroscopic
resection (experimental intervention) or no intervention
(control). Randomisation will be performed by using
ALEA, an online randomisation program, managed by
the Clinical Research Unit in the Academic Medical
Centre in Amsterdam, with the use of permuted blocks
with a random block size of 2 to 4 patients per block,
stratified for participating centres.
At the time of randomisation, baseline, obstetric and
medical history are reported in the case report file. The
patient will receive digital online secured questionnaires at
baseline, 3 and 6 months after randomisation about their
menstrual pattern and uterine bleeding, will complete a
validated menstrual bleeding score chart [28], validated
questions to report on quality of life (SF-36: Short Form
36 [29, 30] and Euro-QOL 5D: Euro Quality of Life in 5
dimensions [31]), sexual function (FSFI: Female Sexual
Fig. 3 Niche measurement during sonohysterography in the sagittal
plane (a), transversal plane (b) with the thinnest residual myometrium
and niche shape will be registered in both planes (c). a Measuring a
niche in the sagittal plane. Schematic drawing demonstrating how
to measure a niche in the sagittal plane. The depth of the niche is
measured from the usual limit of the uterine cavity until the apex of the
niche (1), the residual myometrium from the apex of the niche until
the serosa (2). a is an adapted figure of the one that was published by
Bij de Vaate et al. 2011 [5]. b Measuring a niche in the transversal plane.
Schematic drawing demonstrating how to measure a niche in the
transversal plane. The depth of the niche is measured from the usual
limit of the uterine cavity until the apex of the niche (1) and the residual
myometrium from the apex of the niche until the serosa (2). c Niche
shape. Schematic diagram demonstrating classification used to assess
niche shape as published by Bij de Vaate et al. 2011: triangle, semicircle,
rectangle, circle, droplet and inclusion cysts [5]
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Health and Labour [33]). Medical consultation, me-
dication use and received additional therapies will be
registered at the same timepoints in an online diary. Any
received additional therapy will be registered in the case
report file.
Three months after randomisation all patients will
undergo transvaginal sonography to register all niche
features as at baseline. Patients will be motivated to
undergo a SIS or GIS, however saline or gel instillation
will be omitted in case patients experienced too much
discomfort during this procedure at baseline (see Fig. 4
for the flowchart).
Intervention (hysteroscopic niche resection)
The patients allocated for hysteroscopic niche resection
will undergo the procedure under spinal or general an-
aesthesia in ambulatory setting. After dilatation of the
cervical os up to Hegar 9 mm, the hysteroscopic resec-
tion will be performed using a 9 mm resectoscope in a
standardized way, as described below. In case of bipolar
currency, 0.9 % NaCL and in case of monopolar cur-
rency, sorbitol fluid will be used to induce distension of
the uterine cavity. The niche will be evaluated by hyster-
oscopy and standardized characteristics will be regis-
tered (Fig. 5).
The bladder will be filled with methylene blue solution
during the procedure to enable early identification of
eventual bladder injuries. The procedure will be per-
formed under continuous combined sonographic evalu-
ation to ensure sufficient distance between the resection
and coagulation area and the bladder. The distal rim of
the niche in utero, if prominent visible, will be resected
(Fig. 6) as described by i.a. Chang et al. and Fabres et al.
and the niche surface will be superficially coagulated.
Eventual polyps in the niche will be resected. A max-
imum fluid loss of 1000 ml Sorbitol or 2000 ml NaCl is
accepted. Surgical outcomes such as satisfaction of the
gynaecologist, surgical steps, complications and postop-
erative hospital stay will be registered in the case report
file. Name and experience in numbers of resections of
the gynaecologist with hysteroscopic niche resections
will be registered. All gynaecologists will be evaluated in
performing the resection using an Objective Structured
Assessment of Technical Skills (OSATS). In case of an
uneventful procedure, patients will be discharged on the
same day.
Control group (expectant management)
The control group will receive no additional intervention
during the first six months after randomisation. Patients
will be encouraged to continue the medication and/or
oral contraceptives during this period as used before
randomisation. Six months after randomisation all types
Fig. 4 Flowchart. * Questionnaires: Menstruation questionnaire, SF-36 (Short Form-36 [29, 30]), Euro-Qol 5D [31], FSFI (Female Sexual Function
Index) [32], menstruation chart [28], costs and consultation diary, HLQ (Health and Labour Questionnaire) [33]
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given up to six months will be registered in both the inter-
vention and the control group, such as oral contraceptives,
IUD placement or hysterectomy.
Outcome measures
The primary outcome is the number of days with post-
menstrual spotting during one menstrual cycle 6 months
after randomisation.
Secondary outcomes are the menstrual characteristics,
menstrual related pain and experienced discomfort of
both spotting and menstrual pain on VAS of 0–10),
quality of life (SF-36, EuroQoL5D, patient satisfaction
(5 point scale), sexual function (FSFI), micturition fre-
quency, and urinary incontinence, absence from work
(HLQ: Health and Labour [33]), medical consultation,medication use and received additional therapies (diary) at
3 and 6 months after randomisation.
Sample size
Based on a systematic review of the literature executed
in 2011 we identified one relevant manuscript reporting
on a reduction in postmenstrual abnormal uterine
bloodloss (PAUB) with an estimated median reduction
of 3.8 days after a hysteroscopic niche resection com-
pared to baseline [27]. At baseline, included patients had
mean spotting of 7.5 days with a standard deviation of
2.7. Estimated postmenstrual spotting reduced from 7.5
to 3.7 days (see box and whisker plots). Given the fact
that the ranges at baseline and after therapy were more
or less similar we estimated the SD to be approximately
2.7. However given the lack of a control group without
Fig. 5 Schematic diagram of niche characteristics during hysteroscopy
Vervoort et al. BMC Women's Health  (2015) 15:103 Page 6 of 9treatment it cannot be excluded that regression to the
mean have played a role and may have induced an
overestimation of the effect. Given these uncertainties
we decided to base our sample size on the difference in
postmenstrual spotting days that were considered to be
clinically relevant and this should be lower than theFig. 6 Resection of the distal part of the niche. Is a modified figure
of the one that was published by Gubbini et al. 2008 [18] and
v.d. Voet et al. [26]previously reported difference of 3.8 in order to prevent
insufficient power. Based on experience and confirmed
in a survey among patients (unpublished), we considered
2 days to be clinically relevant and a dropout rate of
20 % to be realistic and used these parameters to calcu-
late a sample size to achieve a power of 90 %.
In summary, assuming a difference of postmenstrual
spotting of 2 days to be clinical relevant with an
estimated SD of 2.7, a dropout rate of 20 %, we need to
include 50 patients in each arm to achieve a power of
90 %.
Statistical analysis
Analyses will be performed according to intention-to-treat
principle and additionally by per protocol analysis. All
tests will be performed two sided and a p-value <0.05 will
be considered as statistically significant. The difference
between the two groups at 6 months follow-up regarding
total number of postmenstrual spotting days during one
menstrual cycle, duration of menstrual bleeding, number
of days of brownish discharge, menstrual pain, experi-
enced discomfort of spotting and of menstrual pain, SF-36
domain scores and EuroQol will be analysed using linear
regression analyses, adjusted for relevant baseline values.
Potentially relevant confounders are additional hormonal
therapy, smoking and use of anticoagulation. Logistic
regression analysis will be used to evaluate the existence
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with treatment, reported on a 0–5 point scale at six
months a (multinominal) logistic regression analysis will
be used.
We have planned four subgroup analyses, for:
1) Total days of spotting at the end of the menstruation
and intermenstrual spotting >25th centile versus ≤ 25th
centile and >75th centile or ≤75th centile at baseline;
2) Number of days postmenstrual spotting >25th centile
versus ≤2 25th centile and >75th centile versus ≤75th
centile at baseline;
3) Small versus larger niches (using a cut-off of
residual myometrium of 3 and 5 mm and <50 % of total
myometrial thickness (sum of RM and niche depth) at
baseline;
4) A history of 1 versus more than 1 CS at baseline.
Economic evaluation
The economic evaluation will be performed alongside
the randomised controlled trial. Both a cost-effectiveness
analysis as a cost-utility analysis will be performed from
the societal perspective. In the cost-effectiveness ana-
lysis, the reduction in postmenstrual spotting days will
be used as the primary outcome. In the cost-utility
analysis, societal costs will be related to QALYs over
6 months. Costs that will be included are direct health-
care costs (costs of the hysteroscopic niche resection,
use of healthcare services such as outpatient visits, hos-
pital admissions, laboratory and imaging tests, visits to
health care providers outside the hospital, medication,
etcetera), direct non-healthcare costs (i.e. informal care),
and indirect non-healthcare costs (absenteeism and pre-
senteeism from paid and unpaid work).
We hypothesize that hysteroscopic niche resection will
reduce postmenstrual spotting and related medical con-
sultations, applied therapies and sick leave and as a
consequence will be cost-effective in comparison with
the expectant management strategy.
Analyses will be performed according to the intention-
to-treat principle. Missing cost and effect data will be
imputed using multiple imputation [34]. The imputation
will include variables that are related to missing data or
the outcome measure, and variables that differ at base-
line between the groups. To account for the skewed dis-
tribution of costs predictive mean matching will be used
in the multiple imputation. The number of imputed data
sets to be created will be determined based on the
fraction of missing information [35]. All datasets will be
analyzed separately and the results of the 20 analyses
will be pooled using Rubin’s rules [36]. Incremental cost
effectiveness ratios (ICERs) will be calculated by dividing
the differences in mean total costs between both treat-
ment groups, by the difference in mean effects between
both treatment groups [36]. To avoid double counting,productivity costs due to sick leave will be excluded in
the ICER with sick leave as effect measure. The incre-
mental cost utility ratio will be calculated by dividing the
incremental costs by the difference in QALYs between
both treatment groups. To account for the typically
skewed distribution of costs, bias-corrected and acceler-
ated bootstrapping (5000 replications) will be used to es-
timate the 95 % confidence intervals around the mean
cost differences and the uncertainty surrounding the
ICERs. The bootstrapped ICERs will be graphically pre-
sented in cost-effectiveness planes [37]. Cost-effectiveness
acceptability curves will be estimated to show the prob-
ability of the intervention program to be cost-effective in
comparison with usual care for a range of different ceiling
ratios, thereby showing decision uncertainty [38].
Interim analysis and safety monitoring
Because of the relatively small sample size and the
expected duration of inclusion no interim analysis for
efficacy is planned. All Serious Adverse Events (SAE’s)
will be reported to the Medical Ethics Committee. In
case of two Serious Adverse Events (SAE’s) related to the
study intervention the Data Safety Monitoring Committee,
will be notified. The DMC can advise to terminate the trial
prematurely for safety reasons. All adverse events will be
followed until they have abated, or until a stable situation
has been reached. Depending on the event, follow up may
require additional tests or medical procedures as indi-
cated, and/or referral to the general physician or a medical
specialist.
Ethical considerations
This study is approved by the National Central Committee
on Research involving Human Subjects (CCMO –
NL38397.029.11), by the ethics committee of the VU
Medical Centre Amsterdam (Ref. No. 2011/397) and by
the boards of all participating hospitals. The trial is
registered in the Dutch Trial Register (NTR3269, http://
www.trialregister.nl).
Discussion
Only recently, we became aware of an association
between niches in the CS uterine scar and bleeding
disorders [5, 6, 9–12]. Postmenstrual spotting is present
in approximately 20 % of women after a CS. Several in-
novative surgical therapies to reduce these complaints
have been developed [26]. Currently, the least invasive
surgical therapy is the hysteroscopic resection of the
niche. So far only a few studies reported on hystero-
scopic resections. Success rates on reduction of post-
menstrual spotting are high and no complications are
reported [15, 18–23, 26, 27]. However exact method-
ology, follow-up or (validated) tools to measure outcomes
are mostly not reported and sample sizes were small.
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This trial is the first randomised controlled trial that will
provide evidence for the (cost) effectiveness of hystero-
scopic resection of a niche versus expectant management
in women with niche related postmenstrual spotting.
The HysNiche study is adequately powered. Randomisa-
tion is performed with the use of allocation concealment
through a webbased randomisation program, which re-
duces the chance for bias. The study is not blinded for the
patient, which could possibly effect reported outcomes by
the patient. We found it ethically not justified to ask
patients to undergo a hysteroscopic procedure without
performing the resection, because of the risk on complica-
tions due to the hysteroscopy or anesthesia and possible
pain complaints after the procedure.
Furthermore the HysNiche study will evaluate quality
of life and sexual function in relation to complaints of
spotting, which was not reported in earlier studies.
None of earlier studies reported on cost-effectiveness
of a hysteroscopic niche resection compared to ex-
pectant management. We assume a hysteroscopic niche
resection to be more cost-effective, since we expect it to
prevent the need for invasive surgical interventions such
as a hysterectomy due to therapy resistant spotting or
menstrual pain. We expect postoperative recovery time
to be short and medical consultation to be less frequent.
And not irrelevant, we think quality of life could improve
with the knowledge of having low health care costs.
Questionnaires used are not adjusted or validated for
spotting complaints. Disease specific validated question-
naires have not been developed yet.
Different methods of performing a hysteroscopic re-
section are described. In some studies only the distal rim
of the niche is resected [15, 20, 21, 27], whereas in other
studies the distal and proximal part of the niche is
resected [18, 19, 22, 23]. In some studies the fragile
vessels in the bottom of the niche are coagulated
[18, 19, 21–23], while in other studies the entire niche
surface is coagulated [15, 20]. It is unclear if authors used
different descriptions of the same procedure (i.e. if the
resection of the proximal part of the niche is the same as
coagulation of the vessels in the entire niche surface.
Given the fact that it can not be excluded that proximal
resection could harm the strength of the cervix and may
induce unneeded cervical incompetence in case of a sub-
sequent pregnancy we decided to omit this part of the
procedure. In addition niche resection is expected to in-
crease the size of the niche and resection of both distal
and proximal part may induce unneeded increase of the
size of the niche. Based on theory we hypothesized that in
particular the distal rim may impair normal outflow of
menstrual blood. And as a consequence we expect that re-
section of the distal rim of the niche will improve blood
flow towards the cervix. In addition we expect thatsuperficial coagulation of the vessels of the niche surface
is sufficient to prevent bleeding from potentially fragile
niche vessels.
Potential impact and implications
This trial will provide evidence for patients, healthcare
providers and policy makers on the (cost) effectiveness
of hysteroscopic resection of a niche versus expectant
management in women with postmenstrual spotting and
a niche with sufficient residual myometrium to perform
a hysteroscopic niche resection. It is important to realize
that not all niches cause symptoms, and as the treatment
is predominantly performed to relieve symptoms, niches
without symptoms should not be treated by a hystero-
scopic niche resection. In addition it is important to
realize that we only include patients with relatively small
niches thus the outcomes can’t be extrapolated to
patients with large niches. In patients with large niches,
i.e. thin residual myometrium of less then 3 mm a hys-
teroscopic niche resection is expected to be at higher
risk of bladder injury and uterine perforations.
Based on results of this study, implementation of the
hysteroscopic niche resection in daily practice can be
discussed and long-term complications of a CS can pos-
sibly be reduced. The patient reported outcomes could
inform future patients about the expected outcomes of
both niche resection and expectant management and
support shared decision making.
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